Transcode Therapeutics (RNAZ) Insider & Congress Trades

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about RNAZ filings

Are insiders buying or selling Transcode Therapeutics Inc (RNAZ) stock?

Neither. Transcode Therapeutics Inc (RNAZ) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded RNAZ recently?

None. No member of Congress disclosed a RNAZ trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this RNAZ smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

1 fund holds a position.

Questions about RNAZ filings

Are insiders buying or selling Transcode Therapeutics Inc (RNAZ) stock?

Neither. Transcode Therapeutics Inc (RNAZ) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded RNAZ recently?

None. No member of Congress disclosed a RNAZ trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this RNAZ smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 14, 2026

Period ending

Jun 30, 2026

Earnings per share

Unavailable

EPS comparison unavailable

Revenue (6M)

$0.00

6M ended Jun 30, 2026 · SEC filing · No operating revenue

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 13, 2026	Not on file	No estimate	Not on file	Not on file
Jun 30, 2026Reported Aug 14, 2026	-$7.17Reported	No estimate	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported Apr 15, 2026	-$21.28Reported	No estimate	$0.00SEC filing	No year-ago quarter
Dec 31, 2025Reported Feb 25, 2026	-$16.42Reported	No estimate	Not on file	Not on file
Sep 30, 2025Reported Nov 14, 2025	-$5.82est. -$1.02	-$4.80miss	Not on file	Not on file
Jun 30, 2025Reported Aug 14, 2025	-$5.13est. -$1.64	-$3.49miss	Not on file	Not on file
Mar 31, 2025Reported May 14, 2025	-$1286.15est. -$89.88	-$1196.27miss	Not on file	Not on file
Dec 31, 2024Reported Apr 15, 2025	-$1286.15est. -$89.88	-$1196.27miss	$0.00Yahoo Finance	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.53
High: $1.56
Low: $1.45
Prev close: $1.51
52-wk high: $12.60
52-wk low: $1.33
Mkt cap: $23.7M
ROE: -59.3%
Beta: 1.27
P/B: 2.8x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $24M

Valuation

P/B2.83

Quality

Operating margin0.0%
ROE-59.3%
ROA-19.9%

Growth

Beta1.27

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

33balanced

20D volatility

69%annualized

52-week range

$1.49

$1.33$12.60

20D support

$1.45recent floor

20D resistance

$1.91recent ceiling

Returns

5D -8.6%20D -19.9%60D -57.2%

Price vs moving averages

SMA20 -10.6%SMA50 -14.2%SMA200 -75.0%

Volume pace

0.50xvs prior 20D

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about RNAZ filings

Are insiders buying or selling Transcode Therapeutics Inc (RNAZ) stock?

Neither. Transcode Therapeutics Inc (RNAZ) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded RNAZ recently?

None. No member of Congress disclosed a RNAZ trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this RNAZ smart-money data?

No recent filings found.

1 fund holds a position.

Questions about RNAZ filings

Are insiders buying or selling Transcode Therapeutics Inc (RNAZ) stock?

Neither. Transcode Therapeutics Inc (RNAZ) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded RNAZ recently?

None. No member of Congress disclosed a RNAZ trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this RNAZ smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 14, 2026

Period ending

Jun 30, 2026

Earnings per share

Unavailable

EPS comparison unavailable

Revenue (6M)

$0.00

6M ended Jun 30, 2026 · SEC filing · No operating revenue

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 13, 2026	Not on file	No estimate	Not on file	Not on file
Jun 30, 2026Reported Aug 14, 2026	-$7.17Reported	No estimate	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported Apr 15, 2026	-$21.28Reported	No estimate	$0.00SEC filing	No year-ago quarter
Dec 31, 2025Reported Feb 25, 2026	-$16.42Reported	No estimate	Not on file	Not on file
Sep 30, 2025Reported Nov 14, 2025	-$5.82est. -$1.02	-$4.80miss	Not on file	Not on file
Jun 30, 2025Reported Aug 14, 2025	-$5.13est. -$1.64	-$3.49miss	Not on file	Not on file
Mar 31, 2025Reported May 14, 2025	-$1286.15est. -$89.88	-$1196.27miss	Not on file	Not on file
Dec 31, 2024Reported Apr 15, 2025	-$1286.15est. -$89.88	-$1196.27miss	$0.00Yahoo Finance	No year-ago quarter

Open: $1.53
High: $1.56
Low: $1.45
Prev close: $1.51
52-wk high: $12.60
52-wk low: $1.33
Mkt cap: $23.7M
ROE: -59.3%
Beta: 1.27
P/B: 2.8x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $24M

Valuation

P/B2.83

Quality

Operating margin0.0%
ROE-59.3%
ROA-19.9%

Growth

Beta1.27

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

33balanced

20D volatility

69%annualized

52-week range

$1.49

$1.33$12.60

20D support

$1.45recent floor

20D resistance

$1.91recent ceiling

Returns

5D -8.6%20D -19.9%60D -57.2%

Price vs moving averages

SMA20 -10.6%SMA50 -14.2%SMA200 -75.0%

Volume pace

0.50xvs prior 20D

Transcode Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about RNAZ filings

Questions about RNAZ filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Transcode Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about RNAZ filings

Questions about RNAZ filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Transcode Therapeutics Inc

Overview

Questions about RNAZ filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Transcode Therapeutics Inc

Overview

Questions about RNAZ filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.